The startup CP2 Biotech, specializing in the development of therapeutic solutions to modulate immune and inflammatory processes underlying various diseases, has begun an incubation path at Bio4Dreams. It will benefit from a network of resources, support, and expertise essential to accelerate its development and bring its products to market.

From CP2 Biotech, molecules to modulate immune and inflammatory responses

Founded in 2020 as a spin-off of the University of Milano-Bicocca, CP2 Biotech focuses on researching and developing molecules capable of modulating the activity of the TLR4 receptor, a crucial “switch” regulating the body’s immune and inflammatory responses. These molecules aim to become innovative treatments for chronic and acute inflammations linked to severe—and even rare—diseases such as autoimmune, fibrotic, and oncological conditions.

With the motto from bench to bedside, the startup seeks to bridge the gap between academic research and clinical application, translating laboratory discoveries into practical therapies for patients. It leverages synthetic, semi-synthetic, and natural molecules patented by the University of Milano-Bicocca.

New projects in adjuvants and oncological immunotherapies

Among CP2 Biotech’s main projects are the development of vaccine adjuvants and immunotherapies targeting oncological diseases. Recently, the company has also initiated preclinical testing of TLR4 antagonist molecules to treat autoimmune diseases, with the aim of advancing toward clinical trials in the future.

📗 Learn more about CP2 Biotech and other companies in our portfolio.